SCL Science
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
SCL Science makes medical devices that stop bleeding during surgical and vascular procedures, its flagship product, InnoSEAL, is a hemostatic pad that bonds with blood proteins to control bleeding.
Hospitals and clinicians performing vascular interventions and abdominal surgeries are the primary users of its devices. Listed on KOSDAQ, Korea's tech and small-cap board, the company also runs two other business lines: a temperature-controlled logistics service for biological and pharmaceutical shipments, and a data-platform business offering AI-assisted medical-imaging and health-screening software.
Summary is AI-generated and may contain errors · figures from DART filings
SCL Science in five facts
What does SCL Science do?
SCL Science makes medical devices that stop bleeding during surgical and vascular procedures, its flagship product, InnoSEAL, is a hemostatic pad that bonds with blood proteins to control bleeding.
Where is SCL Science listed and in which sector?
SCL Science (Korean name: SCL사이언스) trades under KRX code 246960 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is SCL Science?
Its market capitalisation was US$59.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were SCL Science's latest annual revenue and operating profit?
For fiscal year 2025, SCL Science reported revenue of US$16.6M, an operating loss of US$2.6M and a net loss of US$3.1M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 364.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- DisclosureOct 16
- Investor relations (IR) meetingOct 6
- [Amended] Supply contract signed
SCL Science updated a previously disclosed supply contract with SCL Healthcare Co., Ltd., now worth US$750K, about 76.82% of its recent annual revenue, running through Dec 2026.
Supply contract · Sep 30 - [Amended] Investor relations (IR) meetingSep 21
- Report on securities held by executives/major shareholdersSep 17
- Investor relations (IR) meetingSep 14
- Supply contract signed
SCL Science disclosed a supply contract, worth US$5.45M, about 35.1% of its recent annual revenue, running through Sep 2029.
Supply contract · Aug 10 - [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
SCL Science updated its previously filed consolidated results for FY2025: revenue of US$15.8M (+381.1% year on year), an operating loss of US$2.37M and a net loss of US$3.8M.
Earnings · Feb 12 · 2 versions - [Amended] Supply contract signedSupply contract · Jan 30